A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
This research study is looking at a new treatment called VTX-801 for adults with Wilson's Disease. VTX-801 is a type of gene therapy, which means it aims to address the root cause of the disease. The study will last up to five years and involves giving the treatment directly into a vein. Researchers will carefully check the safety of VTX-801, how well people tolerate it, and what effects it has on the body. A key part of the study is seeing if patients can gradually reduce their usual Wilson's Disease medications after receiving VTX-801. This is a "Phase I/II" study, meaning it's an early step to understand the treatment better in a small group of people.
A colpo d'occhio
Risultati
Risultati di questo studio
Pubblicato January 2026I risultati di questo studio sono stati pubblicati.
Di cosa tratta questo studio?
Wilson's Disease is a rare genetic condition where too much copper builds up in the body, primarily in the liver and brain. If left untreated, this can cause serious health problems. Current treatments focus on removing excess copper and preventing its build-up, and people usually need to take medication for life.
This study, called a "Phase I/II" study, is investigating a new treatment called VTX-801. VTX-801 is a "gene therapy," which is a type of medicine that tries to correct the problem by introducing a healthy copy of the gene that is faulty in people with Wilson's Disease. The aim is to help the body process copper properly again. This means it could potentially be a long-lasting treatment.
The main goals of this study are to find out if VTX-801 is safe for adults with Wilson's Disease and how well their bodies handle it. Researchers also want to see what effects the treatment has on the body and whether patients might eventually be able to reduce or even stop their regular Wilson's Disease medication. The study will follow participants for up to five years to carefully observe these long-term effects.
Punti chiave
- Tests a new gene therapy (VTX-801) for Wilson's Disease.
- Aims to check safety, tolerability, and effectiveness.
- Could potentially reduce the need for current medications.
- Involves treatments given into a vein.
- Requires commitment for up to five years of monitoring.
- Only for adults aged 18-65 with stable Wilson's Disease.
Chi può essere idoneo?
To join this study, you would need to be an adult between 18 and 65 years old with an official diagnosis of Wilson's Disease. You should also be currently receiving treatment for your Wilson's Disease according to standard medical advice and your condition needs to have been stable for at least one year. This means your symptoms haven't changed much, and tests that check copper levels are steady.
There are also some reasons why you might not be able to join. For example, if you have certain liver problems, such as signs of serious liver damage or abnormal results in some blood tests (like those for liver function or blood clotting), you wouldn't be eligible. The study also cannot include individuals with significant kidney problems, or certain infections like HIV or hepatitis. People with a history of diabetes or high body mass index (BMI) over 35 kg/m2 would also be unable to participate.
If you are pregnant or breastfeeding, or if you have any other serious health conditions or medications that might interfere with the study, you would not be able to take part. The research team will carefully review all your medical information to make sure joining the study is safe for you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai tra i 18 e i 65 anni?
- Have you been officially diagnosed with Wilson's Disease?
- Have you been receiving standard treatment for your Wilson's Disease, and has your condition been stable for at least one year?
- Do you have good overall liver and kidney function according to your doctor?
- Are you free from certain infections like HIV or hepatitis?
- Non sei incinta o stai allattando?
Cosa comporta la partecipazione?
If you join this study, you would receive the study medicine, VTX-801, which is given through a drip into your vein (intravenous infusion). The study plans to test different doses of VTX-801. After receiving the treatment, researchers will closely monitor you to see how your body reacts and if your current Wilson's Disease treatment can be gradually reduced or even stopped.
Your participation would involve regular visits to the study clinic for up to five years. During these visits, the research team would conduct various assessments. These might include physical examinations, blood and urine tests, and other procedures to check your health, how well the treatment is working, and to monitor for any side effects. These assessments help the doctors understand the safety and effects of VTX-801 over time. The exact number and frequency of visits would be detailed by the study team.
Rischi e benefici potenziali
Locations (10)
- UC Davis Medical CenterCodice postale verificatoSacramento, Stati Uniti
- Yale University School of MedecineCodice postale verificatoNew Haven, Stati Uniti
- Advent HealthCodice postale verificatoOrlando, Stati Uniti
- University of Michigan Health SystemCodice postale verificatoAnn Arbor, Stati Uniti
- Wake Forest School of MedicineCodice postale verificatoWinston-Salem, Stati Uniti
- University of Texas Southwestern Medical CenterCodice postale verificatoDallas, Stati Uniti
- Aarhus University HospitalCodice postale verificatoAarhus, Danimarca
- Ospedale Universitario di EssenCodice postale verificatoEssen, Germania
- Universitätsklinikum Tübingen (UKT)Codice postale verificatoTübingen, Germania
- Ospedale della Contea di Royal SurreyCodice postale verificatoGuildford, United Kingdom
Domande comuni
What is Wilson's Disease?
Wilson's Disease is a genetic condition where your body collects too much copper, which can harm organs like your liver and brain.
What is a 'gene therapy'?
Gene therapy is a new type of treatment that tries to fix the root cause of a disease by adding or changing genes in your body.
What does 'Phase I/II' study mean?
This means it's an early-stage study designed to first check the safety of a new treatment and then see if it has a positive effect in a small group of people.
How long would I be in the study?
You would be part of the study for up to five years, involving regular check-ups and monitoring.
Will I still take my regular Wilson's Disease medicine?
The study aims to see if you can gradually reduce or stop your current Wilson's Disease medication after receiving the study treatment.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.